RxDoctor Payments Data

Jonathan Zenilman, MD

Infectious Disease · Baltimore, MDNPI 1730119264

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $196,254 of the $201,887 with a category attached, or 97.2%. Pfizer accounts for 98.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $57,056 and has fallen 73.7% since, to $14,988 in 2025. Among infectious disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$201,887in general payments, 2019–2025

Across 135 payments — averaging $1495.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$199K
  • Siemens Medical Solutions USA, Inc.$2K
  • Cipla USA Inc.$500
  • Tetraphase Pharmaceuticals, Inc.$113
  • Orasure Technologies Inc.$27

What the payments were for

  • Consulting fees$196,25497%
  • Speaking & faculty fees$1,3901%
  • Travel & lodging$3,4002%
  • Food & beverage$8380%
  • Gifts$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$201,887 in reported general payments places this provider in the 95th percentile of 289 infectious disease providers in Maryland.

See all infectious disease providers in Maryland

Medicare billing

Part B allowed, 2024
$2,714
Medicare patients
14
Services billed
16

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →